Report from Karolinska Development AB's Extraordinary General Meeting, December 21, 2010
STOCKHOLM - December 21, 2010 - Report from the Extraordinary General Meeting in Karolinska Development AB (publ).
The Extraordinary General Meeting (the "Meeting") has elected Michael Rosenlew as director of the board. Information regarding Michael Rosenlew is available on the company's web site; www.karolinskadevelopment.com.
The meeting also authorized the board for the period up to the next annual shareholders' meeting to adopt decisions, whether at one or several occasions and whether with or without pre-emption rights for the shareholders, to issue new shares of Series A and/or Series B; provided however that any such issue must not result in the company's number of shares increases by more than 24,000,000 shares.
The authorization replaces the authorization by the annual general meeting 2010, regarding new issue of no more than 8,000,000 shares.
The remuneration for the board of directors is as decided at the annual general meeting.
For further information, please contact:
Hans Wigzell, Chairman of the board, Karolinska Development
Phone: +46 (0) 705 76 05 39, e-mail: hans.wigzell@ki.se
Conny Bogentoft, CEO, Karolinska Development
Phone: +46 (0) 706 68 61 43, e-mail: conny.bogentoft@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development
Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique business model, the company cost efficiently guides the commercialization of world class life science innovations. Since its inception in 2003, Karolinska Development has built a portfolio of some 40 companies. Among the company's projects, 12 candidate drugs are undergoing clinical trials and it is estimated that more than 20 substances have first-in-class potential. www.karolinskadevelopment.com